George Schroeder, MD
Addiction Medicine · Ormond Beach, FLNPI 1265530760
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $65,899 of the $67,703 with a category attached, or 97.3%. Novartis accounts for 97.4% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2021 at $21,187 and has fallen 99.9% since, to $17 in 2025. Among addiction medicine clinicians in FL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 182 payments — averaging $372.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novartis$66K
- Johnson & Johnson$969
- GSK$183
- Pfizer$121
- Boehringer Ingelheim$94
- Amgen$92
- plus $333 from 7 others
What the payments were for
- Consulting fees$65,89997%
- Food & beverage$1,7863%
- Education$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novartis | 156 | $65,911 |
| Johnson & Johnson(2 entities) | 13 | $969 |
| GSK | 2 | $183 |
| Pfizer | 1 | $121 |
| Boehringer Ingelheim | 1 | $94 |
| Amgen | 1 | $92 |
| AstraZeneca | 1 | $89 |
| Novo Nordisk | 1 | $71 |
| Janssen Scientific Affairs, LLC | 1 | $68 |
| Insmed, Inc. | 2 | $41 |
| Amarin Pharma, Inc. | 1 | $36 |
| Teleflex LLC | 1 | $16 |
| Abbott | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$67,703 in reported general payments places this provider in the 95th percentile of 101 addiction medicine providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 164 | $130,196 |
| InvokanaCanagliflozin | 129 | $79,874 |
| XareltoRivaroxaban | 23 | $20,464 |
| MyrbetriqMirabegron | 26 | $20,396 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 23 | $17,240 |
| Fenofibrate | 1,166 | $13,600 |
| NamzaricMemantine Hcl/Donepezil Hcl | 21 | $10,885 |
| Rosuvastatin Calcium | 1,189 | $7,340 |
| VascepaIcosapent Ethyl | 21 | $6,050 |
| Ezetimibe | 865 | $5,525 |
| Liothyronine Sodium | 170 | $5,291 |
| Methylprednisolone | 505 | $3,007 |
| Metoclopramide Hcl | 399 | $2,946 |
| Ketorolac Tromethamine | 266 | $2,878 |
| Pioglitazone Hcl | 248 | $1,705 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $121 | $130,196164 claims |
| Johnson & JohnsonInvokana, Xarelto | $969 | $100,339152 claims |
| GSKTrelegy Ellipta | $183 | $17,24023 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 101 addiction medicine providers in Florida.
Other addiction medicine in Ormond Beach
- Mark GoldGainesville$355K
- Mark JacksonSaint Augustine$225K
- David KirbyLake City$183K
- Brian GadboisTampa$50K
- Timothy GoodenNavarre$40K
- John TannerJacksonville Beach$29K
- Malissa BarbosaOrlando$28K
- Thomas RineyPace$21K
- Rachael SanchezJacksonville$12K
- Miguel CorreaLeesburg$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.